133 related articles for article (PubMed ID: 26943653)
1. Quality by design approach for development of suspension nasal spray products: a case study on budesonide nasal suspension.
Chudiwal SS; Dehghan MH
Drug Dev Ind Pharm; 2016 Oct; 42(10):1643-52. PubMed ID: 26943653
[TBL] [Abstract][Full Text] [Related]
2. Quality by design (QbD) approach for design and development of drug-device combination products: a case study on flunisolide nasal spray.
Chudiwal SS; Dehghan MHG
Pharm Dev Technol; 2018 Dec; 23(10):1077-1087. PubMed ID: 27616074
[TBL] [Abstract][Full Text] [Related]
3. Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach.
Chudiwal VS; Shahi S; Chudiwal S
Drug Dev Ind Pharm; 2018 May; 44(5):787-799. PubMed ID: 29198152
[TBL] [Abstract][Full Text] [Related]
4. Risk Assessment Integrated QbD Approach for Development of Optimized Bicontinuous Mucoadhesive Limicubes for Oral Delivery of Rosuvastatin.
Javed MN; Kohli K; Amin S
AAPS PharmSciTech; 2018 Apr; 19(3):1377-1391. PubMed ID: 29388027
[TBL] [Abstract][Full Text] [Related]
5. Engineering of budesonide-loaded lipid-polymer hybrid nanoparticles using a quality-by-design approach.
Leng D; Thanki K; Fattal E; Foged C; Yang M
Int J Pharm; 2018 Sep; 548(2):740-746. PubMed ID: 28847667
[TBL] [Abstract][Full Text] [Related]
6. QbD for pediatric oral lyophilisates development: risk assessment followed by screening and optimization.
Casian T; Iurian S; Bogdan C; Rus L; Moldovan M; Tomuta I
Drug Dev Ind Pharm; 2017 Dec; 43(12):1932-1944. PubMed ID: 28748713
[TBL] [Abstract][Full Text] [Related]
7. Implementation of Quality by Design for Formulation of Rebamipide Gastro-retentive Tablet.
Ha JM; Seo JW; Kim SH; Kim JY; Park CW; Rhee YS; Park ES
AAPS PharmSciTech; 2017 Nov; 18(8):3129-3139. PubMed ID: 28526986
[TBL] [Abstract][Full Text] [Related]
8. QbD-enabled systematic development of gastroretentive multiple-unit microballoons of itopride hydrochloride.
Bansal S; Beg S; Asthana A; Garg B; Asthana GS; Kapil R; Singh B
Drug Deliv; 2016; 23(2):437-51. PubMed ID: 24865292
[TBL] [Abstract][Full Text] [Related]
9. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis.
Salapatek AM; Lee J; Patel D; D'Angelo P; Liu J; Zimmerer RO; Pipkin JD
Allergy Asthma Proc; 2011; 32(3):221-9. PubMed ID: 21477425
[TBL] [Abstract][Full Text] [Related]
10. A quality by design approach to understand formulation and process variability in pharmaceutical melt extrusion processes.
Patwardhan K; Asgarzadeh F; Dassinger T; Albers J; Repka MA
J Pharm Pharmacol; 2015 May; 67(5):673-84. PubMed ID: 25615235
[TBL] [Abstract][Full Text] [Related]
11. Elucidation of Formulation and Delivery Device-Related Effects on In Vitro Performance of Nasal Spray with Implication to Rational Product Specification Identification.
Grmaš J; Stare K; Božič D; Injac R; Dreu R
J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):230-246. PubMed ID: 28075184
[TBL] [Abstract][Full Text] [Related]
12. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
[TBL] [Abstract][Full Text] [Related]
13. A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation.
Aksu B; Paradkar A; de Matas M; Özer Ö; Güneri T; York P
Pharm Dev Technol; 2013 Feb; 18(1):236-45. PubMed ID: 22881350
[TBL] [Abstract][Full Text] [Related]
14. Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation.
Pozzoli M; Rogueda P; Zhu B; Smith T; Young PM; Traini D; Sonvico F
Drug Dev Ind Pharm; 2016 Oct; 42(10):1660-8. PubMed ID: 26953090
[TBL] [Abstract][Full Text] [Related]
15. Quality by design approach for the preparation of fat-soluble vitamins lipid injectable emulsion.
Deng Y; Zhong G; Wang Y; Wang N; Yu Q; Yu X
Int J Pharm; 2019 Nov; 571():118717. PubMed ID: 31610279
[TBL] [Abstract][Full Text] [Related]
16. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.
Pallagi E; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2015 Aug; 491(1-2):384-92. PubMed ID: 26134895
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the particle size distribution and rheology of brinzolamide ophthalmic suspensions.
Vo A; Feng X; Patel D; Mohammad A; Kozak D; Choi S; Ashraf M; Xu X
Int J Pharm; 2020 Aug; 586():119495. PubMed ID: 32553495
[TBL] [Abstract][Full Text] [Related]
18. Quality by design I: Application of failure mode effect analysis (FMEA) and Plackett-Burman design of experiments in the identification of "main factors" in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets.
Fahmy R; Kona R; Dandu R; Xie W; Claycamp G; Hoag SW
AAPS PharmSciTech; 2012 Dec; 13(4):1243-54. PubMed ID: 22993122
[TBL] [Abstract][Full Text] [Related]
19. Application of ICH Q9 Quality Risk Management Tools for Advanced Development of Hot Melt Coated Multiparticulate Systems.
Stocker E; Becker K; Hate S; Hohl R; Schiemenz W; Sacher S; Zimmer A; Salar-Behzadi S
J Pharm Sci; 2017 Jan; 106(1):278-290. PubMed ID: 27842971
[TBL] [Abstract][Full Text] [Related]
20. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery.
Nolan LM; Tajber L; McDonald BF; Barham AS; Corrigan OI; Healy AM
Eur J Pharm Sci; 2009 Jul; 37(5):593-602. PubMed ID: 19463948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
